Drug intelligence / Profile preview

Tegaderm CHG

Development stage
Unknown
Lead developer
3M
Modality
Small Molecules
Administration
Topical
01

Overview

Tegaderm CHG is a transparent intravenous (IV) securement dressing that integrates a chlorhexidine gluconate (CHG) gel pad within a breathable film dressing. The product is designed to cover and protect catheter sites and secure devices to the skin while providing immediate and continuous antimicrobial protection for up to 7 days. The integrated gel pad contains 2% w/w chlorhexidine gluconate, an antiseptic agent with broad-spectrum antibacterial and antifungal activity. This combination reduces catheter-related bloodstream infections (CRBSI) and vascular catheter colonization by suppressing regrowth of microorganisms commonly associated with these infections. The transparent film acts as a waterproof barrier against external contaminants, including bacteria, viruses (27 nm or larger), yeast, and fluids, while allowing continuous site observation[1][3][6]. Clinical studies have shown that use of this dressing significantly reduces CRBSI rates compared to standard dressings but may increase the incidence of contact dermatitis[5][6]. It is not indicated for use on premature infants or infants younger than two months due to risk of hypersensitivity reactions or necrosis[1][8].

Brand names
Tegaderm CHG
Other names
3M Tegaderm CHG3M Tegaderm CHG Chlorhexidine Gluconate I.V. Securement DressingTegaderm CHG Dressing

Beyond the preview

Go deeper on Tegaderm CHG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tegaderm CHG.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call